Non-AIDS-Defining Cancers in People Living with HIV
Keith M. Sigel, MD, PhD, MPH
Associate Professor, Medicine, General Internal Medicine
Associate Professor, Medicine, Infectious Diseases
Associate Professor (Pending), Otolaryngology
Icahn School of Medicine at Mount Sinai, New York, NY
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2023. All rights reserved.
Click here to take the CME Evaluation and Post-Meeting Survey
Keith Sigel is an Associate Professor in the Division of General Internal Medicine. Dr. Sigel is a clinical investigator and epidemiologist with a primary research interest in clinical factors related to the abnormal biology of cancers in the setting of chronic infections, particularly HIV and human papilloma virus (HPV). His clinical interests include issues associated with the care of aging HIV infected patients with a particular interest in cancer risk and management in this group. He has served as the primary care physician for a panel of patients with HIV since 2009.
Dr. Sigel received his BS, MPH, and MD degrees from the University of North Carolina at Chapel Hill and his PhD from the Icahn School of Medicine at Mount Sinai. He completed his internal medicine residency at Mount Sinai in 2005, serving as a chief resident, and went on to complete fellowships in General Internal Medicine and Infectious Diseases at Mount Sinai. Dr. Sigel directs the Cancer Core of the Veterans national HIV cohort (the Veterans Aging Cohort Study) and is a member of the executive committee of that cohort. He has served as principal investigator for major NCI funded studies on the screening and treatment of lung cancer in people living with HIV and is currently the principal investigator of an NIH-funded trial studying novel approaches to cancer screening in HIV uninfected women with HPV infection.
At the completion of this educational session, learners will:
1. Understand the contemporary epidemiology of non-AIDS-defining cancers.
2. Be aware of unique cancer screening issues for people living with HIV.
3. Understand mechanisms driving cancer risk for people living with HIV.
4. Appreciate potential unique issues surrounding cancer treatment in people living with HIV.
This CME activity has approved for
AMA PRA Category 1 Credit™ for February 8, 2023 as a live activity.
This activity will also be available as an enduring activity from February 9, 2023, through February 7, 2026.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0
AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to one (1) Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
As an ACCME-accredited provider, MSSNY is required to identify and mitigate relevant financial relationships of all individuals in control of CME content. Financial relationships are relevant if the following three conditions are met for the prospective person who will control content of the education: A financial relationship, in any amount, exists between the person in control of content and an ineligible company; The financial relationship existed during the past 24 months; The content of the education is related to the products of an ineligible company with whom the person has a financial relationship.
- Dr. James F. Braun (Planner/Course Director/Moderator) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Course Moderator) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Research grants from: ViiV and Gilead. All relevant financial relationships have been mitigated.
- Dr. Keith M. Sigeli (Presenter) has no relevant financial relationships to disclose. Dr. Sigel submitted their slides in advance for adequate peer review and will support their presentations and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare
Download Article PDF/Slides